$10.45
0.656.63%
Last update: Nov 6, 4:00 PM
DBV Technologies SA (DBVT) Stock Price, Quote, News & History
DBVTNASDAQ
DBV Tech (DBVT) maintains progress with BLA submission for VIASKIN peanut patch in children. Analyst maintains Buy rating with $51 target.
You can purchase shares of DBV Technologies (NASDAQ:DBVT) through any online brokerage.
Other companies in DBV Technologies’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
DBV Technologies has a consensus price target of $27.81.
The stock price for DBV Technologies (NASDAQ: DBVT) is $10.45 last updated November 6, 2026 at 4:00 PM EST.
There are no upcoming dividends for DBV Technologies.
DBV Technologies does not have any upcoming earnings scheduled.
There is no upcoming split for DBV Technologies.
DBV Technologies is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or...
